Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses a real problem. Diabetes and obesity have been on the rise for decades, cause severe strain on healthcare systems, and are projected to worsen.

However, Ozempic comes with potential drawbacks, one of which is muscle loss. Several companies are looking to address that problem, including Abbott Laboratories (NYSE: ABT) and Regeneron Pharmaceuticals (NASDAQ: REGN). Let's find out what these two healthcare leaders are doing and whether it makes their shares worth buying.

Regeneron's management recently discussed the muscle-loss problem that therapies like Ozempic bring with them. According to the company, it has been shown that as much as 40% of the weight-loss that patients experience while on Ozempic is due to a decrease in lean muscle mass.

Continue reading

Source Fool.com